Type I interferons in anticancer immunity

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474

Innate and adaptive immune cells in the tumor microenvironment

Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148

Virus interference. I. the interferon

Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451

The Three Es of Cancer Immunoediting

Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,235

Type I interferons in infectious disease

McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917

Ultra-pH-sensitive nanoparticle of gambogenic acid for tumor targeting therapy via anti-vascular strategy plus immunotherapy

Deng, L., Wei, T., Zhang, Y., Shen, A., He, X., Gao, S., Li, X. B., He, W., Haleem, A., Hu, R., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124303 · Cited by 7

Effector Functions of Dendritic Cells in Cancer: Role of Cytotoxicity and Growth Inhibition

Chaudhary, P., Srivastava, P., & Manna, P. P. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2908293 · Cited by 8

The importance of IFNα2A (Roferon-A) in HSV-1 latency and T cell exhaustion in ocularly infected mice

Wang, S., Jaggi, U., Katsumata, M., & Ghiasi, H. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012612 · Cited by 7

Cytosolic bacterial pathogens activate TLR pathways in tumors that synergistically enhance STING agonist cancer therapies

Danielson, M., Nicolai, C. J., Vo, T. T., Wolf, N. K., & Burke, T. (2024) · iScience · doi:10.1016/j.isci.2024.111385 · Cited by 8

Single-cell analysis of signalling and transcriptional responses to type I interferons

Rigby, R. E., Rue-Albrecht, K., Fedorov, A., Sims, D., & Rehwinkel, J. (2026) · EMBO Reports · doi:10.1038/s44319-026-00750-3 · Cited by 7

Targeted Stat2 deletion in conventional dendritic cells impairs CTL responses but does not affect antibody production

Qiu, C. C., Kotredes, K. P., Cremers, T., Patel, S., Afanassiev, A., Slifker, M. J., Gallucci, S., & Gamero, A. M. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1860477 · Cited by 7

A Monocyte-Orchestrated IFN-I–to–IL-4 Cytokine Axis Instigates Protumoral Macrophages and Thwarts Poly(I:C) Therapy

Guo, P., Yang, L., Zhang, M., Zhang, Y., Tong, Y., Cao, Y., & Liu, J. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001411 · Cited by 7

Carbonic Anhydrase IX (CAIX) Expressing Hypoxic Micro-environment Hampers CD8+ Immune Cell Infiltrate in Breast Carcinoma

Juhász, P., Hasulyó, D., Bedekovics, J., Beke, L., Kacsala, N., Török, M., & Méhes, G. (2022) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001082 · Cited by 7

Dichotomous roles of RIPK3 in regulating the IFN response and NLRP3 inflammasome in human monocytes

Yang, C., Yuan, R., Brauner, C., Du, Y., Kioon, M. D. A., Barrat, F. J., & Ivashkiv, L. B. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad095 · Cited by 7

ACTION INTERFERONS AND IFN-INDUCTORS ON TLR/RLRS GENES EXPRESSION AND DIFFERENTIATION OF TUMOR CELL LINES THP-1 AND HCT-116

Tm, S., Васильевич, П. В., Burova, O. S., Николаевич, Ш. А., Za, S., Inshakov, A. N., Shishkin, Y. V., & Fi, E. (2016) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2016-15-3-28-33 · Cited by 7

Cancer therapy with major histocompatibility complex‐deficient and interferon β‐producing myeloid cells derived from allogeneic embryonic stem cells

Umemoto, S., Haruta, M., Sakisaka, M., Ikeda, T., Tsukamoto, H., Komohara, Y., Takeya, M., Nishimura, Y., & Senju, S. (2019) · Cancer Science · doi:10.1111/cas.14144 · Cited by 7

Identification of a prognostic classifier based on EMT-related lncRNAs and the function of LINC01138 in tumor progression for lung adenocarcinoma

Xiao, L., Huang, Y., Li, Q., Wang, S., Ma, L., Fan, Z., Tang, Z., Yuan, X., & Лю, Б. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.976878 · Cited by 7

Losses of cytokines and chemokines are common genetic features of human cancers: the somatic copy number alterations are correlated with patient prognoses and therapeutic resistance

Wong, H. S.-C., & Chang, W. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1468951 · Cited by 7

A NanoBRET-based assay monitoring interactions in the USP18 signaling hub identifies the first cell-penetrant small molecule compromising USP18/ISG15 bindingPreprint

Hess, S., Alonso, M. C., Brand, M. J. D., Lauw, S., Lindenmann, U., Göbel, K., Geurink, P. P., Fritz, G., Riedl, R., & Knobeloch, K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.30.646166 · Cited by 7

Identification of tumour‐infiltrating myeloid subsets associated with overall survival in lung squamous cell carcinoma

Lu, J., Duan, Y., Liu, P., He, X., Yang, Y., Zhang, R., & Weng, L. (2023) · The Journal of Pathology · doi:10.1002/path.6015 · Cited by 6

An overview of the functions and mechanisms of APOBEC3A in tumorigenesis

Yang, Y., Liu, N., & Gong, L. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.08.020 · Cited by 6

Olaparib and Radiotherapy Induce Type I Interferon– and CD8+ T Cell–Dependent Sensitization to Immunotherapy in Pancreatic Cancer

Valvo, V. M., Zhang, Q., Jiang, L., Holcomb, E. A., Pearson, A. N., Edmunds, A. G., Faulkner, H., James, J. G., Tate, A., Huber, A. K., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0210 · Cited by 6

A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer

Gwin, W. R., Salazar, L. G., Dai, J. Y., Higgins, D. M., Coveler, A. L., Childs, J. S., Blancas, R., Dang, Y., Reichow, J. L., Slota, M., et al. (2025) · Vaccines · doi:10.3390/vaccines13020117 · Cited by 6

Optogenetic‐Controlled iPSC‐Based Vaccines for Prophylactic and Therapeutic Tumor Suppression in Mice

Qiao, L., Niu, L., Wang, Z., Dai, D., Tang, S., Ma, X., Deng, Z., Yu, G., Zhou, Y., Yan, T., et al. (2025) · Advanced Science · doi:10.1002/advs.202416115 · Cited by 6

Regulatory T Cells in Colon Cancer: Implications for Pathogenesis, Prognosis and Emerging Therapeutic Strategies

Muhammad, F. A., Shareef, A., Jyothi, S. R., Kumar, S., Chauhan, A. S., Gautam, A., Джамшедовна, А. М., Sameer, H. N., Yaseen, A., Athab, Z. H., et al. (2025) · Immunological Investigations · doi:10.1080/08820139.2025.2529970 · Cited by 7

Trends and hotspots in research related to tumor immune escape: bibliometric analysis and future perspectives

Zhu, H., Huang, Y., Wang, X., Xiang, W., & Xie, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1604216 · Cited by 6

Interferon signaling and STING pathway in head and neck cancers: unlocking immune secrets and therapeutic frontiers

Zolfaghari, K., Yazdi, M., Mohammadioun, S., Tajafrooz, F., Malekfarnood, H., Saleki, K., & Rezaei, N. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03963-z · Cited by 6

EP300 compromises antitumor immunity by increasing SOCS1 expression

Zeng, Y., Zhou, Y., Ruan, J., Liu, W., Fan, H., Liu, N., Li, L., Ma, J., Jin, X., Duan, L., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011488 · Cited by 6

TRIM21 regulation of IRF-mediated type I interferon signaling in systemic autoimmune diseases

Panlu, K., Wang, Y., Zhu, X., Lin, Z., Fang, T., Yao, X., Xie, Z., & Wang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1695818 · Cited by 6

Neutrophil-hijacking vesicles suppress NET-mediated metastasis via targeted siRNA delivery after radiotherapy

Cao, H., Mi, J., Wang, S., Gui, H., Wang, H., Liu, J., & Liu, J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114634 · Cited by 6

Single-cell profiling of tumor lineage plasticity and the immune microenvironment in transformed small cell lung cancer

Huang, J., Zhang, Z., Cai, G., Huang, W., Chen, Y., Zhang, J., Yang, L., Zhou, Q., Yang, J., & Wang, J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07940-6 · Cited by 6

Cancer stem cell immunoediting by IFNγ

Galassi, C., & Galluzzi, L. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06079-2 · Cited by 6

Design, synthesis, and cell-based in vitro assay of deoxyinosine-mixed SATE-dCDN prodrugs that activate all common STING variants

Xie, Z., Yang, Y., Ma, D., & Xi, Z. (2023) · Organic & Biomolecular Chemistry · doi:10.1039/d3ob01838e · Cited by 6

Preclinical Evaluation of 131I/18F-Labeled Covalent Small-Molecule Inhibitors for STING Status Imaging

Fang, J., Wang, X., Meng, L., Zhang, J., Zhuang, R., Li, Y., Zhang, X., & Guo, Z. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00398 · Cited by 7

Picrasidine S Induces cGAS‐Mediated Cellular Immune Response as a Novel Vaccine Adjuvant

Ding, X., Sun, M., Guo, F., Qian, X., Yuan, H., Lou, W., Wang, Q., Lei, X., & Zeng, W. (2024) · Advanced Science · doi:10.1002/advs.202310108 · Cited by 7

Probing the Topological Effects on Stability Enhancement and Therapeutic Performance of Protein Bioconjugates: Tadpole, Macrocycle versus Figure‐of‐Eight

Liu, Y., Tian, X., Zhang, F., & Zhang, W. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400466 · Cited by 6

Study on the Recombinant Human Interferon α1b, α2b, and Gamma Transient Expression and in Vitro Activities in Tobacco

Xie, D., Cao, L., Guo, M., Wang, L., Zhang, X., & Huang, S. (2024) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2024.0107 · Cited by 6

Rejuvenation of Tumor‐Specific T Cells via Ultrahigh DAR Antibody‐Polymeric Imidazoquinoline Complexes: Coordinated Targeting of PDL1 and Efficient TLR7/8 Activation in Intratumoral Dendritic Cells

Chu, H., Shan, Y., Liu, Z., Sun, M., Zhao, W., Xie, X., Wang, K., Yang, C., Fang, X., Shen, N., et al. (2025) · Advanced Materials · doi:10.1002/adma.202412974 · Cited by 6

Turning VDR Off to Turn Immunity On: Metadichol Derepresses VDBP in Human Monocytes

Raghavan, P. R. (2026) · Medical Research Archives · doi:10.18103/mra.2026.0394 · Cited by 4

Immunomodulatory antitumor effect of interferon‑beta combined with gemcitabine in pancreatic cancer

Blaauboer, A., van Koetsveld, P. M., Mustafa, D. A. M., Dumas, J., Dogan, F., van Zwienen, S., van Eijck, C. H. J., & Hofland, L. J. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5387 · Cited by 6

After virus exposure, early bystander naïve CD8 T cell activation relies on NAD+ salvage metabolism

Holay, N., Kennedy, B. E., Murphy, J. P., Konda, P., Giacomantonio, M., Brauer-Chapin, T., Paulo, J. A., Kumar, V., Kim, Y., Elaghil, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1047661 · Cited by 6

How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles

Fu, Y., Zeng, C. H., An, C., Liu, Y., Shin, J. H., & Li, X. (2023) · Cancers · doi:10.3390/cancers15041324 · Cited by 6

Phenotypes and Functions of Human Dendritic Cell Subsets in the Tumor Microenvironment

Sakref, C., Bendriss‐Vermare, N., & Valladeau‐Guilemond, J. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-2938-3_2 · Cited by 6

Synergistic immunostimulation for tumor sensitization with a biomineralized DNA sponge

Yu, W., Chen, Y., Yan, M., Xu, Z., Sun, J., Shen, Y., Song, D., Wang, F., & Liu, X. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101996 · Cited by 6

From Local to Systemic Treatment: Leveraging Antitumor Immunity Following Irreversible Electroporation

Stam, A. G. M., & de Gruijl, T. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-55113-5_17 · Cited by 7

Harnessing Genomic Stress for Antitumor Immunity

Pu, C., Tao, S., Xu, J., & Huang, M. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8221 · Cited by 6

Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer

Neulinger, M., Schaack, D., Grekova, S. P., Bauer, A. S., Giese, T., Salg, G. A., Espinet, E., Leuchs, B., Heller, A., Nüesch, J. P. F., et al. (2021) · Viruses · doi:10.3390/v13061019 · Cited by 6

Comprehensive Analysis to Identify the Epithelial–Mesenchymal Transition-Related Immune Signatures as a Prognostic and Therapeutic Biomarkers in Hepatocellular Carcinoma

Wu, G., Yang, Y., Zhu, Y., Li, Y., Zhai, Z., An, L., Liu, M., Zheng, Y., Wang, Y., Zhou, Y., et al. (2021) · Frontiers in Surgery · doi:10.3389/fsurg.2021.742443 · Cited by 6

Type I Interferon Promotes Antitumor T Cell Response in CRPC by Regulating MDSC

Fan, L., Xu, G., Cao, J., Li, M., Zhang, H., Li, F., Qi, X., Zhang, X., Li, Z., Han, P., et al. (2021) · Cancers · doi:10.3390/cancers13215574 · Cited by 6

DNA Damage Repair in Brain Tumor Immunotherapy

Zhao, S., Xu, B., Ma, W., Chen, H., Jiang, C., Cai, J., & Meng, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.829268 · Cited by 6

E3 Ubiquitin Ligase Riplet Is Expressed in T Cells and Suppresses T Cell–Mediated Antitumor Immune Responses

Iwamoto, A., Tsukamoto, H., Nakayama, H., & Oshiumi, H. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100096 · Cited by 6

Oncolytic Rodent Protoparvoviruses Evade a TLR- and RLR-Independent Antiviral Response in Transformed Cells

Angelova, A. L., Pierrard, K., Detje, C. N., Santiago, E., Grewenig, A., Nüesch, J. P. F., Kalinke, U., Ungerechts, G., Rommelaere, J., & Daeffler, L. (2023) · Pathogens · doi:10.3390/pathogens12040607 · Cited by 6

The Cross-Regulation Between Autophagy and Type I Interferon Signaling in Host Defense

Jin, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-0606-2_8 · Cited by 6

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives

Hasselbalch, H. C., Skov, V., Kjær, L., Larsen, M. K., Knudsen, T. A., Lucijanić, M., & Kušec, R. (2022) · Cancers · doi:10.3390/cancers14225495 · Cited by 6

Inhibition of METTL3 by STC-15 induces RNA misprocessing that results in dsRNA formation and activates innate immunityPreprint

Fischl, H., Samuels, T. J., Andrews, B., Vasiliauskaitė, L., Jupp, D., Saunders, C. J., Obacz, J., Ofir-Rosenfeld, Y., & Rausch, O. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.05.692335 · Cited by 6

Evofosfamide Enhances Sensitivity of Breast Cancer Cells to Apoptosis and Natural-Killer-Cell-Mediated Cytotoxicity Under Hypoxic Conditions

Das, S., Venkatesh, G. H., El‐Sayed, W., Khouzam, R. A., Mahmood, A. S., Nawafleh, H. H., Zeinelabdin, N. A., Zaarour, R. F., & Chouaïb, S. (2025) · Cancers · doi:10.3390/cancers17121988 · Cited by 5

Reshaping Tumor-Lymph Node Immune Axis via Targeted Lymphatic Delivery of Dual-Functional Immune Modulator for Enhanced Cancer Immunotherapy

Lim, S. Y., Pin, L., Shin, J. H., Lee, B. S., Kim, S. J., Kim, D., Lyu, S., Kim, B. D., Park, C., Jung, J., et al. (2025) · ACS Central Science · doi:10.1021/acscentsci.5c00509 · Cited by 5

BRRIAR lncRNA alters breast cancer risk by modulating interferon signaling in cis and in trans

Sivakumaran, H., Nair, S., Bitar, M., Lu, X., Wang, L. Q., Liu, J., Karunarathne, D. S., Prakrithi, P., Jacquelin, S., Rivera, S., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02510-8 · Cited by 5

PROTAC-based synthetic lethality strategy endogenously activates systemic STING to boost antitumor immunity

Liu, Y., Jiang, M., Ding, M., Ullah, I., Wang, H., Xie, W., Wang, K., & Yuan, Y. (2026) · Science Advances · doi:10.1126/sciadv.ado7448 · Cited by 5

Low-dose radiotherapy remodels the tumor immune microenvironment via the cGAS–STING pathway: mechanisms, challenges, and combination therapy strategies

He, Y., Zeng, X., Liu, Q., Zhou, L., Tang, Y., Liu, S., Wang, X., Shen, S., Ji, J., Liu, Z., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02634-5 · Cited by 5

Modularly designed hybrid vesicles as dual-adjuvant nanovaccines for cancer immunotherapy

Pan, Y., Tang, Y., Chen, L., Xu, Y., Hu, X., Zhang, J., Zheng, Y., She, P., Rao, L., & Xu, X. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124320 · Cited by 5

The promise of immunotherapeutic strategies to advance cancer treatment in pet dogs

Hampel, J., Cheuk, N., Barbosa, M. M. P., & Fan, T. M. (2024) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.24.08.0532 · Cited by 5

Identification and Validation of Four Serum Biomarkers With Optimal Diagnostic and Prognostic Potential for Gastric Cancer Based on Machine Learning Algorithms

Liu, Y., Bian, B., Chen, S., Zhou, B., Zhang, P., Shen, L., & Chen, H. (2025) · Cancer Medicine · doi:10.1002/cam4.70659 · Cited by 5

Amphiphile Polymer‐Lipidkonjugate zur potenten lymphatischen Anreicherung von TLR7/8‐Agonisten ermöglichen eine örtlich begrenzte Aktivierung des angeborenen Immunsystems

Vrieze, J. D., Louage, B., Deswarte, K., Zhong, Z., Coen, R. D., Herck, S. V., Nuhn, L., Frich, C. K., Zelikin, A. N., Lienenklaus, S., et al. (2019) · Angewandte Chemie · doi:10.1002/ange.201905687 · Cited by 5

Novel therapeutic targets for chronic myelomonocytic leukemia

Lasho, T. L., & Patnaik, M. M. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101244 · Cited by 5

Role of Periostin Expression in Canine Osteosarcoma Biology and Clinical Outcome

Alfino, L., Wilczewski‐Shirai, K. C., Cronise, K. E., Coy, J. W., Glapa, K. E., Ehrhart, E. J., Charles, J. B., Duval, D. L., & Regan, D. P. (2021) · Veterinary Pathology · doi:10.1177/0300985821996671 · Cited by 5

Interval breast cancer is associated with interferon immune response

Ugalde‐Morales, E., Graßmann, F., Humphreys, K., Li, J., Eriksson, M., Tobin, N. P., Lindström, L. S., Vallon‐Christersson, J., Borg, Å., Hall, P. N., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.003 · Cited by 5

Assessment of type I interferon responses as a feature of immunogenic cell death

Forveille, S., Sauvat, A., Zhang, S., Zhao, L., Kroemer, G., & Kepp, O. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.12.028 · Cited by 5

Mechanisms regulating transitory suppressive activity of neutrophils in newborns: PMNs-MDSCs in newborns

Perego, M., Fu, S., Cao, Y., Kossenkov, A. V., Meng, Y., Bonner, E. E., Alicea-Torres, K. M., Liu, W., Jiang, Z., Chen, Z., et al. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.4hi0921-514rr · Cited by 5

Interleukin-34 cancels anti-tumor immunity by PARP inhibitor

Nakamura, T., Kajihara, N., Hama, N., Kobayashi, T., Otsuka, R., Han, N., Wada, H., Hasegawa, Y., Suzuki, N., & Seino, K.-I. (2023) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2023.34.e25 · Cited by 5

Chemotherapy to potentiate the radiation-induced immune response

Lecoester, B., Wespiser, M., Marguier, A., Mirjolet, C., Boustani, J., & Adotévi, O. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.01.004 · Cited by 5

Cyclin-dependent kinase 5 negatively regulates antiviral immune response by disrupting myeloid differentiation primary response protein 88 self-association

Ren, J.-P., Cong, H., Gao, L., Jiang, D., Li, X.-T., Wang, Y., Wang, J., & Tang, T.-S. (2023) · Virulence · doi:10.1080/21505594.2023.2223394 · Cited by 5

Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer

Lei, X., Wang, Y., Broens, C., Borst, J. G., & Xiao, Y. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.07.006 · Cited by 5

The dichotomy of regulatory B cells in cancer versus allergic disease

Dang, M., Yu, J., Galant-Swafford, J., & Karam, S. D. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23633 · Cited by 5

Antitumor activity of pegylated human interferon β as monotherapy or in combination with immune checkpoint inhibitors via tumor growth inhibition and dendritic cell activation

Wang, R., Zhang, T., Lu, Y., Lin, Y., Kou, S., Li, X., Wang, Y., & Xie, L. (2023) · Cellular Immunology · doi:10.1016/j.cellimm.2023.104782 · Cited by 5

DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis

Cao, S., Long, X., Xiao, L., Zhang, P., Shen, M., Chen, F., Bao, C., Zhong, X., Luo, T. L., & Ye, F. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1356778 · Cited by 5

Calreticulin Exposure in Mitotic Catastrophe

Bezu, L., Kepp, O., & Kroemer, G. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1217-0_14 · Cited by 5

Distribution Characteristics and Prognostic Value of Immune Infiltration in Oligometastatic Breast Cancer

Zhou, D., Jiang, K., Hong, R., Lu, Q., Xia, W., Li, M., Zheng, C., Zheng, Q., Xu, F., & Wang, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.747012 · Cited by 5

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma

Johnstone, M. E., Vinaixa, D., Turi, M., Morelli, E., Anderson, K. C., & Gullà, A. (2022) · Cells · doi:10.3390/cells11162519 · Cited by 5

Nanoparticle Delivery of Immunostimulatory Alu RNA for Cancer Immunotherapy

Garland, K. M., Kwiatkowski, A. J., Tossberg, J. T., Crooke, P. S., Aune, T. M., & Wilson, J. T. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0354 · Cited by 5

HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs

Huynh, M., Chang, H. Y., Lisiero, D. N., Ong, I. M., Kashyap, T., Callander, N. S., & Miyamoto, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274704 · Cited by 5

Blinatumomab bridges the gap between leukemia and immunity

Yamazaki, T., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1358335 · Cited by 5

Nucleic Acid Sensing at the Interface Between Innate and Adaptive Immunity

Vanpouille‐Box, C., & Galluzzi, L. (2019) · International review of cytology · doi:10.1016/s1937-6448(19)30030-9 · Cited by 5

Harnessing tumor immune ecosystem dynamics to personalize radiotherapyPreprint

Grass, G. D., Alfonso, J. C. L., Welsh, E. A., Ahmed, K. A., Teer, J. K., Harrison, L. B., Cleveland, J. L., Mulé, J. J., Eschrich, S. A., Enderling, H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.11.944512 · Cited by 5

Cancer Cell-Intrinsic Type I Interferon Signaling Promotes Antitumor Immunity in Head and Neck Squamous Cell Carcinoma

Xie, G., Yang, C., Pang, X., Wu, T.-C., & Gu, X. (2025) · Cancers · doi:10.3390/cancers17081279 · Cited by 4

IL1RA inhibits the progression of oral squamous cell carcinoma by mediating type Ⅰ interferon response

Ding, Y., Shan, Y., Gu, J., Yi, J., & Sun, Z. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102428 · Cited by 4

Targeting monopolar spindle kinase I (Mps1 or TTK) induces radiosensitization in syngeneic models of triple negative breast cancer (TNBC) and potentiates type I interferon (T1IFN) signaling

Jungles, K. M., Bishop, C., Wilson, C., Liu, M., Jungles, K. R., Wilder-Romans, K., Speers, C. W., Pierce, L. J., & Rae, J. M. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101190 · Cited by 4

Innate immunity in tumour immunoediting and immunosurveillance

Zhang, Z., Zhang, Y., & Lieberman, J. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00650-7 · Cited by 4

S-nitrosylation of IRF7 induced by NOS1 expression in melanoma suppresses anti-tumor immunity

Dai, Y., Zeng, S., Li, K., Huang, J., Yang, M., Gao, W., Chen, X., Huang, M., Ye, S., Wang, Q., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-025-08201-y · Cited by 4

Sex-dependent interferon signaling contributes to female-biased vulnerability in Alzheimer’s disease

López-López, V., Iniesta, G., Galán-Ganga, M., Exposito-Coca, A., Durán-Laforet, V., Bhojwani-Cabrera, A. M., Navarrón, C. M., Guillot-Fernández, M., Venero, J. L., Sanchez-Mut, J. V., et al. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03840-0 · Cited by 4

Prologue: About DAMPs, PAMPs, and MAMPs

Land, W. G. (2018) · Springer eBooks · doi:10.1007/978-3-319-78655-1_11 · Cited by 5

Functions and roles of IFIX, a member of the human HIN-200 family, in human diseases

Wang, S., & Bai, J. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04297-w · Cited by 4

Moderate Low UVB Irradiation Modulates Tumor‐associated Macrophages and Dendritic Cells and Promotes Antitumor Immunity in Tumor‐bearing Mice†

Park, G., Cui, Y., Yang, S., Sun, M., Wilkinson, E., Li, H., Zhang, Y. B., Chen, J., Bissonnette, M., Lin, W., et al. (2022) · Photochemistry and Photobiology · doi:10.1111/php.13684 · Cited by 4

Targeted immune activation in pediatric solid tumors: opportunities to complement local control approaches

Vonderhaar, E. P., Dwinell, M. B., & Craig, B. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1202169 · Cited by 4

Novaferon gene modification promotes NK92 cell anti-tumor activity

Zhang, W., Yu, B., Meng, Q., Pu, L., Liu, B., & Li, F. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110613 · Cited by 4

Prognostic model and ceRNA network of m7G- and radiosensitivity-related genes in hepatocellular carcinoma

Liu, M., Zhu, M., Huang, Y., Wu, J., Peng, Z., & Liang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29925 · Cited by 4

Cancer Immunotherapy: Targeting TREX1 Has the Potential to Unleash the Host Immunity against Cancer Cells

Hawillo, K., Kemiha, S., & Técher, H. (2024) · Onco · doi:10.3390/onco4040022 · Cited by 4

The Generation of Genetically Engineered Human Induced Pluripotent Stem Cells Overexpressing IFN-β for Future Experimental and Clinically Oriented Studies

Шевелева, О. Н., Protasova, E., Grigor’eva, E. V., Butorina, N. N., Kuziaeva, V. I., Antonov, D., Melnikova, V. I., Medvedev, S. P., & Lyadova, I. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212456 · Cited by 4

MiRNA affects the advancement of breast cancer by modulating the immune system's response

Fu, Y., Yang, Q., Xu, N., & Zhang, X. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167759 · Cited by 4

A quantum leap in cancer vaccines?

Gilboa, E. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0192-3 · Cited by 4

Development of Higher Molecular Weight of Recombinant Human Interferon Alpha-2a by Albumin Fusion Technology in Methilotropic Yeast Pichia Pastoris

Ningrum, R. A., Herawati, N., & Wardiana, A. (2017) · International Journal on Advanced Science Engineering and Information Technology · doi:10.18517/ijaseit.6.5.912 · Cited by 4

BATF2 expression as a novel marker for invasive phenotype in malignant melanoma

Tagawa, H., Kanemaru, H., Kimura, T., Kuriyama, H., Sawamura, S., Kajihara, I., Miyashita, A., Aoi, J., Fukushima, S., & Ihn, H. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15495 · Cited by 4

Model for predicting age-dependent safety and immunomodulatory effects of STING ligands in non-human primates

Takahama, S., Ishige, K., Nogimori, T., Yasutomi, Y., Appay, V., & Yamamoto, T. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.12.008 · Cited by 4

Impact of Genomic Mutation on Melanoma Immune Microenvironment and IFN-1 Pathway-Driven Therapeutic Responses

Mentucci, F. M., Nuñez, E. A. R., Ercole, A., Silvetti, V., Col, J. D., & Lamberti, M. J. (2024) · Cancers · doi:10.3390/cancers16142568 · Cited by 4

Identification of genetic fingerprint of type I interferon therapy in visceral metastases of melanoma

Vízkeleti, L., Papp, O., Doma, V., Gil, J., Marko‐Varga, G., Kovacs, S., Győrffy, B., Kárpáti, S., & Tı́már, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-77285-x · Cited by 4

Type I interferons and dendritic cells in cancer immunotherapy

(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124

The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation

Musella, M., Galassi, C., Manduca, N., & Sistigu, A. (2021) · Biology · doi:10.3390/biology10090856 · Cited by 45

Type I Interferons and Natural Killer Cell Regulation in Cancer

Müller, L., Aigner, P., & Stoiber, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00304 · Cited by 173

The added value of type I interferons to cytotoxic treatments of cancer

Bracci, L., Sistigu, A., Proietti, E., & Moschella, F. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.008 · Cited by 20

Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications

Musella, M., Manic, G., Maria, R. D., Vitale, I., & Sistigu, A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1314424 · Cited by 147